Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab
Completed · Phase 3
Conditions studied: Melanoma
In brief
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
Key facts
- Study ID
- NCT01515189
- Run by
- Bristol-Myers Squibb
- People needed
- 831
- Starts
- 2012-02-17
- Expected to finish
- 2017-08-17
- Last updated by the study team
- 2019-07-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Unresectable Stage III or Stage IV melanoma
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You may not qualify if…
- Brain metastases with symptoms or requiring treatment
- History of autoimmune disease
Where it is running
- University Of California Los Angeles — Los Angeles, California, United States
- Baptist Cancer Institute — Jacksonville, Florida, United States
- Orlando Health, Inc — Orlando, Florida, United States
- Oncology Specialists, S.C. — Park Ridge, Illinois, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
- Duke University Hospital — Durham, North Carolina, United States
- Providence Portland Medical Center — Portland, Oregon, United States
- St. Luke's Cancer Center - Anderson Campus — Easton, Pennsylvania, United States
- Seattle Cancer Care Alliance — Seattle, Washington, United States
- Local Institution — San Miguel de Tucumán, Tucumán Province, Argentina
- Fundacion Cidea — Buenos Aires, Argentina
- Local Institution — Camperdown, New South Wales, Australia
- Local Institution — Coffs Harbour, New South Wales, Australia
- Local Institution — Brisbane, Queensland, Australia
- Local Institution — Southport, Queensland, Australia
- Local Institution — Adelaide, South Australia, Australia
- Local Institution — Heidelberg, Victoria, Australia
- Local Institution — Linz, Austria
- Local Institution — Vienna, Austria
- Local Institution — Brussels, Belgium
- Local Institution — Leuven, Belgium
- Local Institution — Edmonton, Alberta, Canada
- Local Institution — Halfax, Nova Scotia, Canada
- The Angeles Clinic And Research Institute — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.